newsfilter
← Latest News
Business Wire·

PolarityTE Submits Investigational New Drug Application for SkinTE® in Chronic Cutaneous Ulcers

PolarityTE, Inc. (NASDAQ:PTE) today announced the submission of an investigational new drug application (IND) to the United States Food and Drug Administration (FDA) seeking authorization to commence a clinical trial to evaluate its SkinTE product for t